Table 1 Baseline demographic and clinical characteristics of patients assessed before HSCT because of high-risk for development SOS.
N | DS | Age/Gender | Reason for baseline FS | N of factors | Donor | Planned protocol | Actual protocol | LSM kPa | Specific decisions per FS | Type of change | SOS after HSCT/severity |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 | AML | 22/F | -2nd HSCT/ Multiple lines of Tx/Active disease/TBI | 4 | Haplo father | TBF | FLUTBI | 10.1 | No DAC | Composition change | No |
2 | sAML | 40/F | -2nd HSCT -Multiple lines of Tx -DAC | 3 | Haplo brother | TBF-RIC | TBF-RIC | 7 | No specific decision | No | Yes/Moderate |
3 | AML | 23/M | Elevated liver enzymes | 1 | Sibling 10/10 | FLUBU4 | BUCY | 4.9 | Despite liver enzymes elevation - MAC BUCY | Intensification | No |
4 | sAML | 42/F | -Alcohol abuse -Fatty liver | 2 | MUD 10/10 | FLUBU4 | FLU Treo 14 | 7.4 | Treo instead of BU | Composition change | Yes/Mild |
5 | AML | 60/F | -Age -2nd HSCT -Multiple lines of Tx - Previous post CTX severe liver toxicity | 4 | Sibling 10/10 | FLUBU2 | FLU Treo 12 | 3.3 | RTC instead RIC | Intensification | No |
6 | MF | 37/M | -MF -Severe splenomegaly -Susp PHTN | 3 | MUD 10/10 | TBF | TBF MUC | 10.2 | No specific decision | No | No |
7 | MF | 51/M | -MF - Severe PHT d/t Portal vein thrombosis - Previous post CTX severe liver toxicity | 3 | Sibling 10/10 | TBF | FLU Treo 12 | 22.5 | Liver biopsy –N, No DAC, No BU, No MTX | Composition change | Very Severe/death |
8 | sAML | 65/F | - Age - Fatty liver with NASH + liver cirrhosis - Past CTX for Ca of Breast | 4 | Haplo son | TBF | Baltimore RIC protocol mini dose FCYTBI 200 RAD | 18 | RIC/No DAC/Prophylactic Defibrotide | Composition change+ Deintensification | No |
9 | MF | 46/M | -MF -Severe splenomegaly -Susp PHTN | 3 | Haplo son | TBF MAC | TBF RIC | 11.6 | RIC | Deintensification | No |
10 | MF | 65/M | -MF -Severe splenomegaly -Susp PHTN -Age -Fatty liver disease | 5 | Sibling 10/10 | TBF | TBF RIC | 13.8 | RIC | Deintensification | No |
11 | sAML | 43/F | -Active disease -Primary hemochromatosis -Periodic Elevated liver enzymes | 3 | Sibling 10/10 | FLUBU4 or FLU Treo12 | FLU Treo12 | 5.1 | RTC | No specific decision | No |
